UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

International journal of oncology, 2017-12, Vol.51 (6), p.1860-1868

2017

Volltextzugriff (PDF)

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

Journal of medical virology, 2023-01, Vol.95 (1), p.e28139-n/a

2023

Volltextzugriff (PDF)

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Current cancer drug targets, 2023-01, Vol.23 (2), p.103-117

2023

Volltextzugriff (PDF)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211006957-17588359211006957

2021

Volltextzugriff (PDF)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Journal of experimental & clinical cancer research, 2020-09, Vol.39 (1), p.1-18, Article 198

2020

Volltextzugriff (PDF)

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Hepatobiliary & pancreatic diseases international, 2021-12, Vol.20 (6), p.530-534

2021

Volltextzugriff (PDF)

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Engineering (Beijing, China), 2019-10, Vol.5 (5), p.940-947

2019

Volltextzugriff (PDF)

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

Cancer letters, 2007-11, Vol.257 (2), p.157-164

2007

Volltextzugriff (PDF)

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

Virology journal, 2021-11, Vol.18 (1), p.237-237, Article 237

2021

Volltextzugriff (PDF)

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Oncology reports, 2016-11, Vol.36 (5), p.2763-2770

2016

Volltextzugriff (PDF)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920920069-1758835920920069

2020

Volltextzugriff (PDF)

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Drug discovery today, 2021-08, Vol.26 (8), p.1857-1874

2021

Volltextzugriff (PDF)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Frontiers in oncology, 2019-12, Vol.9, p.1377-1377

2019

Volltextzugriff (PDF)

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Journal of experimental & clinical cancer research, 2016-04, Vol.35 (70), p.70, Article 70

2016

Volltextzugriff (PDF)

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Heliyon, 2024-04, Vol.10 (7), p.e28218-e28218, Article e28218

2024

Volltextzugriff (PDF)

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Biochimica et biophysica acta. Reviews on cancer, 2020-12, Vol.1874 (2), p.188425, Article 188425

2020

Volltextzugriff (PDF)

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Molecular oncology, 2014-05, Vol.8 (3), p.469-482

2014

Volltextzugriff (PDF)

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Emerging microbes & infections, 2020-01, Vol.9 (1), p.962-975

2020

Volltextzugriff (PDF)

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

Frontiers in microbiology, 2018-11, Vol.9, p.2724-2724

2018

Volltextzugriff (PDF)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Journal for immunotherapy of cancer, 2019-09, Vol.7 (1), p.250-250, Article 250

2019

Volltextzugriff (PDF)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

Molecular cancer, 2011-07, Vol.10 (1), p.82-82, Article 82

2011

Volltextzugriff (PDF)

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Biochimica et biophysica acta. Reviews on cancer, 2020-04, Vol.1873 (2), p.188360-188360, Article 188360

2020

Volltextzugriff (PDF)

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Drug discovery today, 2021-01, Vol.26 (1), p.106-121

2021

Volltextzugriff (PDF)

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.75-75, Article 75

2019

Volltextzugriff (PDF)

Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor

Current cancer drug targets, 2013-07, Vol.13 (6), p.686-697

2013

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(170)

Publikationsform

Artikel
(189)
Tagungsberichte
(3)

Sprache

Englisch
(114)
Chinesisch
(79)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(73)
Humans
(65)
Animals
(47)
Oncology
(34)
Mice
(30)
Cell Line, Tumor
(23)
Receptor Tyrosine Kinase
(16)
Mice, Inbred Balb C
(14)
Transfection
(13)
Female
(12)
Proteins
(12)
Receptor Protein-Tyrosine Kinases - Metabolism
(12)
Therapeutic Efficacy
(12)
Apoptosis
(10)
Apoptosis - Drug Effects
(10)
Cell Line
(10)
Clinical Trials
(10)
Kinases
(10)
Monoclonal Antibody
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor

Aktive Filter

Suchergebnisse filtern